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Empiric Antibiotics for Sepsis
Sara A. Buckman, Isaiah R. Turnbull, and John E. Mazuski
Abstract
Background: Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection.
Early recognition and treatment are the cornerstones of management.
Methods: Review of the English-language literature.
Results: For both sepsis and septic shock ‘‘antimicrobials [should be] be initiated as soon as possible and within one
hour’’ (Surviving Sepsis Campaign). The risk of progression from severe sepsis to septic shock increases 8% for each
hour before antibiotics are started. Selection of antimicrobial agents is based on a combination of patient factors,
predicted infecting organism(s), and local microbial resistance patterns. The initial drugs should have activity against
typical gram-positive and gram-negative causative micro-organisms. Anaerobic coverage should be provided for
intra-abdominal infections or others where anaerobes are significant pathogens. Empiric antifungal or antiviral
therapy may be warranted. For patients with healthcare-associated infections, resistant micro-organisms will further
complicate the choice of empiric antimicrobials. Recommendations are given for specific infections.
Conclusion: Early administration of broad-spectrum antimicrobial drugs is one of the most important, if not the
most important, treatment for patients with sepsis or septic shock. Drugs should be initiated as soon as possible,
and the choice of should take into account patient factors, common local pathogens, hospital antibiograms and
resistance patterns, and the suspected source of infection. Antimicrobial agent therapy should be de-escalated as
soon as possible.
Keywords: antimicrobial de-escalation; antimicrobials; sepsis
Sepsis is life-threatening organ dysfunction causedby a dysregulated host response to infection [1]. Globally,
there are more than 31.5 million cases of sepsis each year,
resulting in at least 5.3 million deaths annually [2]. Early rec-
ognition and treatment are the cornerstones of management. To
accomplish this, it usually is necessary to initiate therapy on the
basis of clinical criteria alone, prior to obtaining definitive
microbiologic data [3]. Current guidelines recommend initia-
tion of empiric antimicrobial agents within the first hour after
the recognition of sepsis or septic shock [4]. These guidelines
uniformly emphasize that early antimicrobial drug therapy
should be broad-spectrum, as inadequate or inappropriate an-
tibiotics are an important determinant of in-hospital death in
critically ill patients in the intensive care unit (ICU) [5–11].
Nonetheless, it may be difficult to provide an appropriate em-
piric regimen to every patient, given the wide variety of in-
fections that may be present [12]. General guidance is that the
regimen should be chosen on the basis of the suspected or-
ganism(s) according to the drug susceptibility patterns [13].
Empiric antibiotic selection for septic patients is compli-
cated by the competing obligations to provide broad-spectrum
empiric coverage sufficient to avoid inadequate therapy while
simultaneously adhering to good antibiotic stewardship prac-
tices. Although patients with a drug-resistant infection are at
risk for inappropriate empiric treatment, antibiotic stewardship
guidelines might recommend keeping broader-spectrum agents
in reserve [14,15]. In this paper, we attempt to resolve this
essential tension between the need to treat adequately the in-
dividual patient with sepsis or septic shock and the need to
preserve effective antimicrobial agents for future patients
through appropriate antimicrobial stewardship. We first de-
scribe some of the general principles of antimicrobial agent
therapy in sepsis and septic shock and then provide some
specific guidance with respect to the septic diseases surgical
practitioners are likely to encounter in their practices.
General Principles
Timing of antimicrobial drug administration
The Surviving Sepsis campaign recommends that for both
sepsis and septic shock, ‘‘antimicrobials be initiated as soon
as possible and within one hour’’ [4]. Early administration of
antimicrobial drugs should occur regardless of whether the
patient is in the emergency room, ICU, or general care ward.
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Moderate data support the recommendation for early anti-
biotics. One study showed that patients who received antibi-
otics within one hour of developing hypotension had a higher
survival rate to hospital discharge [16]. Another report found
the odds of death increased by 9% for each hour antibiotics
were delayed in emergency department patients with sepsis,
severe sepsis, or septic shock [17]. A third analysis demon-
strated that the risk of progression from severe sepsis to septic
shock increased 8% for each hour that passed before antibiotics
were started [18]. Early antibiotic therapy also may reduce
pathogen burden, potentially modifying the host response to
infection and reducing subsequent organ dysfuction [19].
Successful initiation of empiric antibiotics for sepsis requires a
high clinical suspicion for infection or worsening organ dys-
function and a dosing regimen that creates therapeutic con-
centrations as soon as possible [20].
General considerations regarding
spectrum of coverage
Although the principles of antimicrobial stewardship in-
clude avoiding injudicious use of broad-spectrum agents,
restrictions resulting in inadequate therapy of the patient
with sepsis or septic shock are not good stewardship. As
indicated previously, inadequate therapy increases the risk
of treatment failure or death [11,21]. Moreover, by failing to
treat an individual patient adequately, while exposing him
or her to agents that will select resistant organisms, inap-
propriate therapy may increase the development of bacterial
resistance.
Selection of antimicrobial agents is based on a combina-
tion of patient factors, predicted infecting organism(s), and
local microbial resistance patterns. Individual patient factors
help to identify those at higher risk of death attributable to
inadequate antimicrobial drug coverage. However, in gen-
eral, any patient meeting the criteria for sepsis or septic shock
is a higher-risk patient and should receive broad-spectrum
parenteral antibiotics. Assessment of individual risk factors
also helps define which patients are at risk for healthcare-
associated infections caused by potentially resistant patho-
gens. Significant medical co-morbidities that may affect drug
pharmacokinetics and pharmacodynamics, such as cirrhosis,
renal disease, or malnutrition, also should be taken into
consideration when selecting specific agents.
For purposes of choosing an empiric antibiotic regimen, in-
fecting bacteria can be broadly classified as gram-positive, gram-
negative, anaerobes, pseudomonads, or resistant (Table 1). In
specific cases, fungal and viral pathogens also may play a role.
The source of the infection will have a large bearing on the
choice of the initial regimen. However, in the setting of sepsis,
the initial drugs should have activity against typical gram-
positive and gram-negative causative micro-organisms. Anae-
robic coverage should be provided for infections, such as
intra-abdominal infections (IAI), where anaerobes are sig-
nificant pathogens. Empiric antifungal or antiviral therapy
may be warranted if there is a strong suspicion that either of
those classes of pathogens is contributing to the patient’s
condition. The drugs chosen need to have adequate tissue
penetration and activity at the suspected source of infection.
Other considerations include the pharmacokinetic and phar-
macodynamic properties of the agent, its bactericidal versus
bacteriostatic activity, and its inherent toxicity [22, 23].
For patients with healthcare-associated infections, clinicians
should be aware of the potential that resistant microorganisms
will further complicate the choice of empiric drugs. Antibiotic
regimens for these infections should be selected on the basis of
known resistant pathogens in the community, as well as hospital
and even unit-specific antibiograms (Table 2). Risk factors for
infections with resistant organisms include hospitalization, prior
residence in another healthcare facility, receipt of home intra-
venous therapy or wound care, or hemodialysis in the last
90 days. Patients who have received immunosuppressive therapy
also are at risk for atypical or resistant pathogens. Patients who
have recently (within 90 days) received broad-spectrum anti-
microbial drug therapy should be treated for potential healthcare-
associated pathogens [21]. Bacteria frequently encountered in
healthcare-associated infections include methicillin-resistant
Staphylococcus aureus and gram-negative bacteria resistant to
a number of classes of antibiotics. Gram-negative organisms
expressing extended-spectrum beta-lactamase may be resistant
to both synthetic penicillins and most cephalosporins.
Carbapenem-resistant Enterobacteriaceae, including those
producing Klebsiella pneumoniae carbapenemases (KPCs) or
even metallo-b-lactamases (NDM-1), are being encountered
increasingly in some parts of the world. These latter bacteria
Table 1. Selected Antimicrobial agents and Spectrum of Coverage
Gram + Gram - Anaerobes Pseudomonas MRSA ESBL VRE
Vancomycin X X
Linezolid X X X
Daptomycin X X X
Piperacillin-tazobactam X X X X
Meropenem X X X X X
Doripenem X X X X X
Imipenem-cilastatin X X X X X
Ertapenem X X X X
Ceftriaxone X X
Cefepime X X X
Ciprofloxacin X X X
Levofloxacin X X X
Metronidazole X
ESBL= extended-spectrumb-lactamase producer; MRSA=methicillin-resistant Staphylococcus aureus; VRE=vancomycin-resistant enterococci.
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are resistant to virtually all b-lactam drugs, although some
new b-lactamase inhibitors may restore the activity of some
beta-lactam antibiotics [24].
Multi-drug and combination therapy
Multi-drug therapy encompasses the both use of multiple
agents to achieve a broad antimicrobial drug spectrum and the
use of multiple antimicrobial agents in combination to target a
specific known or suspected pathogen. This latter use is called
‘‘combination therapy’’ in the current Surviving Sepsis Cam-
paign guidelines, in contrast to the more general term ‘‘multi-
drug therapy’’ [4]. The most common indication for combination
empiric therapy is a higher risk of a resistant pathogen. Empiric
combination therapy can increase the spectrum of coverage,
therefore raising the probability of appropriate initial therapy,
especially in geographic regions where there is high antimicro-
bial drug resistance [19,25]. Combination therapy also may lead
to a lower risk of emergence of resistance [26]. However, the
benefits of combination therapy for the treatment of a specific
pathogen are less well defined. Theoretically, use of multiple
agents with different mechanisms of action would accelerate
pathogen clearance or inhibit the production of microbial viru-
lence factors such as bacterial toxins [27–29]. The disadvantages
Table 2. Antimicrobial Treatment of Specific Infections in Patients with Sepsis or Septic Shock
First-line agent(s) Additive therapy
SSTI
Suspected
monomicrobial
caused by
S. pyogenes
Penicillin G and clindamycin
MRSA Vancomycin OR linezolid Clindamycin for patients with septic shock
Suspected
polymicrobial
Vancomycin OR linezolid OR daptomycin AND
piperacillin/tazobactam OR a broad-spectrum
carbapenem OR a 3rd or 4th generation
cephalosporin plus an anti-anaerobic agent
Clindamycin for patients with septic shock if
potentially caused by streptococcal,
staphylococcal, or clostridial organisms
NSTI Vancomycin OR linezolid OR daptomycin AND
Piperacillin-tazobactam OR a broad-spectrum
carbapenem OR a 3rd or 4th generation
cephalosporin plus an anti-anaerobic agent
Clindamycin for patients with septic shock if
potentially caused by streptococcal,
staphylococcal, or clostridial organisms
Pneumonia
HAP Vancomycin OR linezolid AND Piperacillin-
tazobactam OR cefepime OR levofloxacin OR
imipenem/cilastatin OR meropenem
VAP Vancomycin OR linezolid plus piperacillin-
tazobactam OR cefepime OR levofloxacin OR
imipenem-cilastatin OR meropenem
For septic shock or at higher risk of resistant
gram-negative pathogens, use two agents
from different classes among the following:
Piperacillin-tazobactam, cefepime,
ceftazidime, ciprofloxacin, levofloxacin,
imipenem-cilastatin, meropenem,
aminoglycoside (amikacin, gentamicin,
tobramycin), polymyxin (colistin, polymyxin)
IAI
Higher risk
with CA-IAI
Piperacillin-tazobactam OR imipenem-cilastatin
OR doripenem OR meropenem OR cefepime
plus metronidazole OR ceftazidime plus
metronidazole OR aztreonam plus
metronidazole plus vancomycin
Add ampicillin or vancomycin If using a
cephalosporin-based regimen or a
carbapenem other than imipenem-cilastatin
HA-IAI Piperacillin-tazobactam OR imipenem-cilastatin
OR doripenem OR meropenem OR cefepime
plus metronidazole OR ceftazidime plus
metronidazole OR aztreonam plus
metronidazole plus vancomycin
Add second agent from a different class if there
is a high incidence of resistant gram-negative
pathogens in unit
Add vancomycin if high risk of infection with
Enterococcus spp. If at high risk for
vancomycin-resistant enterococci, add
linezolid or daptomycin
Add an echinocandin if at high risk for a
fungal infection
Add a glycopeptide if patient colonized with
MRSA or at high risk for colonization
Clostridium difficile
Severe-fulminant Oral vancomycin with or without IV
metronidazole
Add rectal vancomycin if colonic ileus is
present
CA-IAI= community-acquired intra-abdominal infection; HAP = healthcare-associated pneumonia; IAI= intra-abdominal infection;
IV = intravenous; MRSA=methicillin-resistant Staphylococcus aureus; NSTI = necrotizing soft-tissue infection; SSTI= skin and soft-tissue
infection; VAP = ventilator-associated pneumonia.
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of using combination therapy are a greater risk of drug toxicity,
especially when aminoglycosides are used; a possibility of su-
perinfection with fungal infections or resistant bacteria; and
higher cost [30–32]. In the current Surviving Sepsis Campaign
guidelines, combination empiric antimicrobial therapy is re-
commended for patients with septic shock but not routinely for
patients at lower risk of death, such as those with sepsis without
septic shock, including those with neutropenia or bacteremia [4].
This recommendation was based on a meta-analysis demon-
strating that combination therapy decreased the mortality rate in
the highest-risk patients but actually increased deaths in lower-
risk patients [33]. If combination empiric therapy is utilized, it
should be discontinued once the patient no longer has evidence
of septic shock. Combination antimicrobial agent therapy also
can be de-escalated to monotherapy once antimicrobial drug
susceptibilities are available, except for those infections, such as
enterococcal endocarditis, where a benefit of combination ther-
apy has been demonstrated clearly [4,34].
De-escalation
‘‘De-escalation’’ of antimicrobial agents refers to either
discontinuing use or narrowing therapy on the basis of culture
and sensitivity results. De-escalation generally can be consid-
ered at 48–72 h once culture and susceptibility data are avail-
able. The action is important to help decrease antimicrobial
resistance, to avoid superinfection with other pathogenic or
resistant organisms, and to prevent the side effects and costs
possible with overuse of broad-spectrum antimicrobial agents
[35]. De-escalation also may involve switching the adminis-
tration route from intravenous to oral or enteral [36]. General
criteria for an intravenous to oral/enteral switch are hemody-
namic stability, clinical improvement (afebrile, reduction in
white blood cell count), a functioning gastrointestinal tract, and
ability to deliver oral/enteral medication [37–39].
There are no studies that have suggested that antimicrobial
de-escalation is harmful if the infecting organism has been
identified or the patient is improving clinically [21,36,40].
One study suggested that de-escalation in patients with severe
sepsis and septic shock was associated with a lower mortality
rate [41]. Although most of the literature on de-escalation re-
lates to patients with ventilator-associated pneumonia (VAP)
and septic shock, de-escalation has proved to be feasible for
surgical patients also [42]. However, de-escalation is practiced
in only 35%–50% of patients, suggesting that this approach
could be utilized much more widely in the interest of promoting
effective antimicrobial stewardship [36]. After de-escalation,
the patient trajectory should continue to be monitored closely.
A worsening of the patient’s condition should prompt further
investigation for a recurrent or potential new source of infec-
tion, including repeat cultures as needed but not an automatic
conclusion that de-escalation has failed.
Duration of therapy
The appropriate duration of antimicrobial drug therapy
depends on the site of infection as well as the patient’s re-
sponse to treatment. Duration should be individualized on the
basis of the severity of illness, the type of infection, whether
source control has been obtained, and diagnostic assessments
of improvement or cure [32]. A standard 7–10 days of therapy
is acceptable for most patients according to current Surviving
Sepsis Campaign guidelines [4]. However, a shorter duration
is appropriate for those patients who have rapid resolution of
symptoms or undergone effective source control, such as
those with complicated intra-abdominal infections (cIAI) who
have received adequate surgery or drainage [34,43]. Pro-
calcitonin measurements have been advocated as a means of
decreasing the duration of therapy [4]. Excessive prolongation
of antibiotic therapy contributes to the development of anti-
microbial drug resistance, amplifies the risk of toxicity, and
increases overall antibiotic costs. Along with de-escalation,
limiting the duration of therapy can be one of the most ef-
fective means of improving antimicrobial stewardship [44].
Treatment of Specific Infections
Skin and soft-tissue infections
Skin and soft-tissue infections (SSTI) are common prob-
lems for which surgical intervention is undertaken. Both non-
necrotizing and necrotizing skin/soft-tissue infections (NSTI)
can lead to sepsis and septic shock, although sepsis is partic-
ularly common with NSTI. As a general principle, empiric
antibiotic therapy of the septic patient with an SSTI should
include agents effective against both gram-positive and gram-
negative and occasionally anaerobic pathogens. Owing to the
high prevalence of methicillin-resistant S. aureus (MRSA)
strains in North America, treatment should include an agent
effective against this organism. Regimens including van-
comycin or linezolid in combination with piperacillin-
tazobactam, a broad-spectrum carbapenem, or a third- or
fourth-generation cephalosporin, potentially with an anti-
anaerobic agent such as metronidazole, are appropriate for
these patients [45,46].
Necrotizing infections are associated with a high mortality
rate and considerable morbidity. Aggressive surgical debride-
ment, broad-spectrum antibiotic therapy, and full supportive
care in an ICU are keys to the treatment of these patients.
These infections fall into three categories: Type I or poly-
microbial NSTI caused by mixtures of aerobic and anaerobic
organisms; Type II or monomicrobial NSTI, typically caused
by Streptococcus pyogenes (group A b-hemolytic streptococci),
although S. aureus infections also can fall into this category; and
the uncommon Type III NSTI associated with Vibrio spp. [47].
Monomicrobial infections caused by Clostridium spp., such as
gas gangrene, can be considered a Type II infection or placed in
a distinct category.
Regardless of the classification, initial empiric antibiotic
therapy for NSTI should be broad and include coverage of
gram-positive, gram-negative, and anaerobic organisms. Be-
cause MRSA may be present, empiric regimens should include
vancomycin, linezolid, or daptomycin. Piperacillin-tazobactam,
a broad-spectrum carbapenem, or a third- or fourth-generation
cephalosporin plus an anti-anaerobic agent also should be part
of the empiric therapy [45,46]. Because of the difficulty in
distinguishing between a Type I and Type II infection, high-
dose clindamycin may be included in the regimen to control
potential Streptococcus pyogenes. Local prevalence of resistant
pathogens as well as hospital- or unit-specific antibiograms and
patient-specific risk factors such as allergies, recent exposure to
the healthcare setting, or recent use of antimicrobial agents
should be factored in when choosing a drug regimen. Once
culture results are available, therapy should tailored to treat the
confirmed pathogens. For Type I infections, anti-MRSA
agents are not needed if MRSA is not found in cultures, and
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anti-gram-negative agents can be discontinued if Pseudo-
monas spp. or other problematic pathogens are not en-
countered. However, therapy still generally will require an
agent or agents effective against common gram-positive,
gram-negative, and anaerobic species. Monomicrobial infec-
tions caused by Group A b-hemolytic streptococci should be
treated with a penicillin and a protein-synthesis inhibitor
such as clindamycin or linezolid; the latter generally can be
discontinued when signs of sepsis have subsided [45,46].
Monomicrobial clostridial infections are treated similarly
using high-dose penicillin and high-dose clindamycin.
Treatment for Type III NSTI caused by Vibrio spp. should
include doxycycline and ceftriaxone or cefotaxime [48].
Antibiotics should be continued until the patient has shown
significant improvement and has been without a fever for 48–
72 h and further debridement is no longer necessary [46].
Toxic shock syndrome (TSS) is a fulminant condition
caused by toxins elaborated by a gram-positive organism,
usually S. pyogenes or S. aureus. It often is part of a localized,
sometimes clinically unapparent, SSTI. However, mortality
rates as high as 70% have been reported for streptococcal
TSS [48,49]. Empiric antimicrobial therapy should include
agents effective against drug-resistant organisms, in addition
to clindamycin or linezolid for reduction of superantigen
production [50–53]. Initial regimens for group A strepto-
coccal TSS include penicillin G and clindamycin, or linezolid
if the patient is intolerant to b-lactam drugs [53,54]. In areas
with a high prevalence of MRSA, the initial regimen should
include either vancomycin and clindamycin or linezolid
monotherapy [53]. Antibiotics should be de-escalated when
culture and susceptibility data are available.
Hospital-acquired and ventilator-associated
pneumonia
Hospital-acquired pneumonia (HAP) and VAP are frequent
complications in surgical patients, especially those who have
sustained traumatic injuries or burns [55]. The Infectious Dis-
eases Society of America and American Thoracic Society
(IDSA/ATS) guidelines released in 2016 define HAP as an
episode of pneumonia developing 48 h or more after hospital
admission which is not associated with mechanical ventilation,
whereas VAP is a pneumonia developing greater than 48 h after
endotracheal intubation [34].
The IDSA/ATS guidelines provide recommendations for
antimicrobial drug treatment of HAP and VAP. Empiric regi-
mens for VAP should include agents effective against S. aureus
and gram-negative bacilli, including P. aeruginosa. It is re-
commended that either vancomycin or linezolid be part of the
initial regimen if the patient is at risk for an infection caused by
MRSA. Such patients include those with septic shock, acute
respiratory distress syndrome before VAP, prior intravenous
antibiotic use within 90 days, hospitalization for five or more
days prior to the diagnosis of VAP, acute renal replacement
therapy before VAP, and those being treated in ICUs where the
incidence of MRSA isolates is greater than 10%–20%. If MRSA
coverage is not indicated, the empiric regimen should include an
agent effective against methicillin-susceptible S. aureus (MSSA)
and gram-negative bacilli, such as piperacillin-tazobactam, ce-
fepime, levofloxacin, imipenem/cilastatin, or meropenem. For
patients in an ICU where >10% of gram-negative isolates are
resistant to a monotherapy agent, or if local antimicrobial sus-
ceptibility rates are not known, two antipseudomonal antimi-
crobial drugs should be started empirically [34].
Once culture results are available, pathogen-directed therapy
can be provided. The IDSA/ATS guidelines favor de-escalation
of antibiotics once definitive results are available but indicate
that clinical trials that weigh the potential influence of de-
escalation on decreasing antimicrobial drug resistance versus
the potential for it to increase the risk of recurrent pneumonia
are needed urgently. For patients with a confirmed pneumonia
caused by P. aeruginosa, there is low-quality evidence sug-
gesting that combination therapy be continued if the patient
remains in septic shock or is considered to be at high risk of
death. The recommended duration of therapy for most patients
with VAP is seven days, although shorter or longer durations
may be appropriate for selected patients [34].
Treatment of patients with suspected HAP parallels that de-
scribed for VAP. Empiric treatment should include coverage of
S. aureus, including MRSA if the patient is at higher risk of
MRSA pneumonia according to the criteria described above.
Empiric treatment for MSSA and gram-negative bacilli is similar
to that for VAP and includes antibiotics active against P. aeru-
ginosa and other gram-negative bacilli. Two antipseudomonal
antibiotics of different classes should be started empirically if
there is a high likelihood of resistant gram-negative isolates. As
with VAP, antibiotic therapy should be de-escalated, if feasible,
and discontinued after seven days [34].
Intra-abdominal infections
Intra-abdominal infections are a common problem faced by
general surgeons. They traditionally have been categorized as
uncomplicated or complicated, with uncomplicated IAI being
those infections limited to a hollow viscus, whereas cIAI are
those with extension into a normally sterile area of the abdomen
[56]. Patients with cIAI also may be described as having sec-
ondary or tertiary peritonitis, single or multiple intra-abdominal
abscesses, or an intra-abdominal phlegmon [57]. Patients can
be designated as having either a community-acquired IAI (CA-
IAI) or healthcare-associated/hospital-acquired IAI (HA-IAI).
Those patients who have an infection developing >48 h after an
initial operation, have been hospitalized for >48 h during the
previous 90 days, have resided in a skilled nursing or other
long-term care facility, have received home infusion or wound
care, or dialysis within the previous 30 days, or who have
undergone treatment with broad-spectrum antibiotics for five
days or more during the previous 90 days are considered to
have HA-IAI. All other patients are deemed to have a CA-IAI;
these patients are further stratified as being at lower or higher
risk of an adverse outcome. Recent guidelines developed by the
Surgical Infection Society (SIS) suggest that patients with
sepsis or septic shock and those with high Acute Physiology
and Chronic Health Evaluation (APACHE) II scores are
higher-risk patients. In addition, multiple factors, including age
70 years or greater, malignant disease, hypoalbuminemia, and
major compromise of cardiovascular, hepatic or renal function
also place the patient at higher risk of an adverse outcome.
Finally, patients with diffuse peritonitis, an elevated Mannheim
peritonitis index score, and those with delayed or inadequate
initial source control should be considered at higher risk [57].
Treatment of patients with cIAI should include medical sta-
bilization, source control, and antibiotic therapy. The empiric
drug therapy for cIAI should include coverage against aerobic
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gram-negative Enterobacteriaceae, aerobic streptococci, and
obligate enteric anaerobic organisms. Treatment options for
lower-risk CA-IAI include ertapenem or moxifloxacin or com-
bination therapy with cefotaxime or ceftriaxone plus metroni-
dazole or ciprofloxacin plus metronidazole. Fluoroquinolones
should be used only if there a significant reaction to b-lactam
antibiotics. Levofloxacin may be substituted for ciprofloxacin if
it is the only formulary fluoroquinolone option.
Because patients with cIAI presenting with sepsis or septic
shock are considered higher-risk patients, certain regimens
generally are recommended. For these patients, therapeutic
options include piperacillin-tazobactam, imipenem-cilastatin,
doripenem or meropenem, cefepime or ceftazidime plus met-
ronidazole, or aztreonam plus metronidazole plus vancomycin.
Addition of ampicillin or vancomycin to provide coverage
of Enterococcus spp. should be considered if using a
cephalosporin-based regimen or a broad-spectrum carba-
penem other than imipenem-cilastatin [57].
Options for empiric antibiotic therapy for patients with HA-
IAI include piperacillin-tazobactam, doripenem, imipenem-
cilastatin, meropenem, cefepime or ceftazidime plus metroni-
dazole, or aztreonam plus metronidazole plus vancomycin. If
there is a high incidence of resistant gram-negative bacteria in
the local setting, a second agent from a different class may be
added. In patients with a risk of infection with Enterococcus
spp., addition of vancomycin is recommended, and for patients
at high risk for infection with vancomycin-resistant entero-
cocci, linezolid or daptomycin is recommended. Patients at
high risk for fungal infections, including those who have re-
cently received long courses of broad-spectrum antibiotic
therapy, those heavily colonized with Candida, and those with
upper-gastrointestinal perforations, recurrent bowel perfora-
tions, or surgically treated pancreatitis should receive empiric
antifungal therapy. For severely ill patients with sepsis or septic
shock, an empiric echinocandin is the drug of choice; it may be
de-escalated to fluconazole as the patient’s condition improves.
Although IAI caused by MRSA is uncommon, empiric use of a
glycopeptide may be warranted in those patients already col-
onized with or at high risk for colonization with MRSA [57].
De-escalation according to definitive culture results is ap-
propriate in patients receiving broad-spectrum therapy, al-
though agents effective against commonEnterobacteriaceae as
well as anaerobic micro-organisms should be continued. Short-
course (four days) antibiotic therapy is now recommended. A
large SIS-sponsored trial demonstrated equivalent outcomes
with shorter as opposed to longer courses of therapy in patients
who had adequate source control [43]. In subgroup analyses, no
benefit of longer courses of drugs was observed in higher-risk
patients or those presenting with sepsis [58–60].
Clostridium difficile infection
Clostridium difficile infection (CDI) is the most common
nosocomial infection affecting the gastrointestinal tract. In
fact, C. difficile has surpassed MRSA as the most common
pathogen causing a hospital-associated bacterial infection
[61,62]. The most common risk factor for CDI is antibiotic
use. Other risk factors are greater age, prior hospitalization,
severe underlying disease, chronic kidney disease, gastroin-
testinal surgical procedures, and immunodeficiency [63–67].
Symptoms range from mild diarrhea to fulminant colitis; the
latter may result in multisystem organ dysfunction and,
eventually, death [68]. Patients with severe CDI have sig-
nificant systemic symptoms and frequently meet the criteria
for sepsis or septic shock [69].
The diagnosis is based on both clinical and laboratory findings.
Most commonly, it is based on a stool test positive for aC.difficile
toxin in a patient with diarrhea; however, in particularly severe
cases in which no diarrhea is present, colonoscopic or histo-
pathologic evidence of pseudomembranous colitis may establish
the cause of the signs and symptoms [70]. The IDSA and Society
for Healthcare Epidemiology of America (SHEA) published
clinical practice guidelines in 2010 for the management of CDI.
When CDI is diagnosed, the suspected offending agent and any
unnecessary antibiotics should be discontinued as soon as pos-
sible. Patients with mild to moderate CDI can receive metroni-
dazole for 10–14 days. For severe or fulminant CDI, however,
oral vancomycin, with per rectum vancomycin if colonic ileus is
present, is the treatment of choice [70,71]. Although it has not not
tested in a rigorous fashion, intravenous metronidazole frequently
is used in combination with oral or enteral vancomycin in se-
verely ill patients. Surgical treatment should be considered in
critically ill patients who have a serum lactic acid concentration
>5 mmol/L or a white blood cell count >50,000/mcL, as these
markers are associated with a higher mortality rate [70,72].
Conclusion
Early administration of broad-spectrum antibiotics is one of
the most important, if not the most important, treatment for
patients with sepsis or septic shock. Drug therapy should be
initiated as soon as possible, preferably within the first hour of
diagnosis. The choice of drugs should take into account patient
factors, common local pathogens, hospital antibiograms and
resistance patterns, and the suspected source of the infection.
Antibiotic therapy should be de-escalated as soon as possible
on the basis of definitive culture results. The duration of anti-
microbial agent therapy should be based on the type of infec-
tion and the patient’s clinical response; increasingly, shorter
courses of therapy have been found to be not only sufficient but
preferable for many of these conditions.
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